Legal Opinion
To: Chongqing Huasen Pharmaceutical Co., Ltd.
Shanghai Zechang Law Firm (hereinafter referred to as "the Firm") has been entrusted by Chongqing Huasen Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") to provide this legal opinion on matters related to the Company's 2025 Annual General Meeting (hereinafter referred to as "the Meeting"). In accordance with the "Company Law of the People's Republic of China" (hereinafter referred to as "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as "Securities Law"), the "Rules for Shareholders' Meetings of Listed Companies" (hereinafter referred to as "Shareholders' Meeting Rules"), and other relevant laws, regulations, and normative documents, as well as the "Articles of Association of Chongqing Huasen Pharmaceutical Co., Ltd." (hereinafter referred to as "Articles of Association"), the Firm has issued this legal opinion. The Firm has appointed lawyers to witness the Meeting.
To issue this legal opinion, the Firm and its lawyers have strictly fulfilled their legal duties in accordance with the "Measures for the Administration of Securities Legal Business of Law Firms" and the "Practice Rules for Securities Legal Business of Law Firms (Trial)". They have adhered to the principles of diligence and good faith, attended the Meeting, and conducted necessary investigations and verifications of the matters involved in the Meeting. The Firm has verified the relevant documents and materials deemed necessary for issuing this legal opinion. The Firm guarantees that the facts identified in this legal opinion are true, accurate, and complete, and that the conclusions expressed are legal and accurate, without any false records, misleading statements, or significant omissions, and is willing to bear corresponding legal responsibilities.
In view of the above, the Firm's lawyers, in accordance with the requirements of the aforementioned laws, regulations, rules, and normative documents, and following the generally recognized business standards, ethical norms, and diligent and responsible spirit of the legal profession, hereby issue the legal opinion as follows:
I. Qualifications of the Convener and Procedures for Convening and Holding the Meeting
(I) Convener of the Meeting
Upon verification, the Meeting was convened by the Company's Board of Directors. To convene this Meeting, the Company held the Sixth Meeting of the Fourth Board of Directors on April 23, 2026, and deliberated and approved the proposal for convening this Meeting.
(II) Convening of the Meeting
On April 24, 2026, the Company published the "Announcement on Convening the 2025 Annual General Meeting of Chongqing Huasen Pharmaceutical Co., Ltd." on the information disclosure media designated by the China Securities Regulatory Commission. The announcement disclosed the convener, method of convening, time, stock registration date, location of the on-site meeting, matters to be deliberated, attendees, and registration methods. The date of the announcement was 20 days prior to the convening of the Meeting, which complies with relevant laws, regulations, normative documents, and the Articles of Association.